Literature DB >> 11292269

Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety.

D Lane1, D Carroll, C Ring, D G Beevers, G Y Lip.   

Abstract

OBJECTIVE: The purpose of this study was to determine the impact of symptoms of depression and anxiety on mortality and quality of life in patients hospitalized for acute myocardial infarction (MI).
METHODS: The Beck Depression Inventory and the State-Trait Anxiety Inventory were completed by 288 patients hospitalized for MI. Twelve-month survival status was ascertained, and quality of life among survivors was assessed at 12 months using the Dartmouth COOP charts.
RESULTS: Thirty-one (10.8%) patients died, 27 of cardiac causes, during the 12-month follow-up. Symptoms of depression and anxiety predicted neither cardiac nor all-cause mortality. Severity of infarction and evidence of heart failure predicted both cardiac and all-cause mortality. The same findings emerged from supplementary analyses of data from patients who died after discharge from the hospital. Symptoms of depression and anxiety, measured at entry, predicted 12-month quality of life among survivors, as did gender, partner status, employment status, living alone, previous frequency of exercise, and indices of disease severity (Killip class and Peel Index). In a multiple regression model in which all of these variables were entered, initial depression scores provided the best independent prediction of quality of life, although living alone, severity of infarction, and state anxiety also entered the model.
CONCLUSIONS: Symptoms of depression and anxiety did not predict either cardiac or all-cause mortality after MI, but they did predict quality of life among those who lived to 12 months.

Entities:  

Mesh:

Year:  2001        PMID: 11292269     DOI: 10.1097/00006842-200103000-00005

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  77 in total

1.  Depression and coronary artery disease: time to move from observation to trials.

Authors:  François Lespérance; Nancy Frasure-Smith
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

2.  Depression, stress, and the heart.

Authors:  P C Strike; A Steptoe
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

Review 3.  Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?

Authors:  Wei Jiang; Ranga R Krishnan
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

4.  Heart disease attributions: introduction to the miniseries.

Authors:  Kenneth E Freedland
Journal:  Int J Behav Med       Date:  2005

5.  Depression, indirect clinical markers of cardiac disease severity, and mortality following myocardial infarction.

Authors:  D Lane; C Ring; G Y H Lip; D Carroll
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

6.  Depression, stress, and coronary heart disease: the need for more complex models.

Authors:  A Steptoe; D L Whitehead
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

7.  Depression and disability in coronary patients: time to focus on quality of life as an end point.

Authors:  D C Haas
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

8.  Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder?

Authors:  Jean-Michel Le Mellédo; Neelam Mahil; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 9.  AAFP guideline for the detection and management of post-myocardial infarction depression.

Authors: 
Journal:  Ann Fam Med       Date:  2009 Jan-Feb       Impact factor: 5.166

10.  Family context influences psychological outcomes of depressive symptoms and emotional quality of life in patients with heart failure.

Authors:  Kelly D Stamp; Sandra B Dunbar; Patricia C Clark; Carolyn M Reilly; Rebecca A Gary; Melinda Higgins; Nadine Kaslow
Journal:  J Cardiovasc Nurs       Date:  2014 Nov-Dec       Impact factor: 2.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.